About Us


Hubro Therapeutics develops immunotherapies for treatment of cancer. Our product candidates are novel neoantigen targeted cancer vaccines for activation of anti-cancer specific T cell immune responses. By providing increased levels of anti-cancer reactive T cells, and by combining with other immune-oncology treatments, it is our desire and sincere hope to improve the lives of cancer patients. 

Our lead candidate product is Framutide, a peptide vaccine corresponding to a fragment of the neo-antigen expressed by cancer cells having a frameshift mutation in the transforming growth factor b receptor 2 (TGFbR2) gene.


30.06.2019;         7.15 million NOK raised in first financing round

29.05.2019;         Patent application covering TGFbR2 neo-antigens filed at The European Patent Office

30.01.2019;         Tax refund programme (Skattefunn) for 2019-2021 approved

14.01.2019;         0.7 million NOK grant received from Innovation Norway